STARTRK-1: phase 1/2a study of entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations - Patel, M; Bauer, T; Liu, S (J Clin Oncol, 2015)
(Suppl): abstract 2596